Direxion Daily Healthcare Bull 3X ETF (CURE)
NYSEARCA: CURE · Real-Time Price · USD
101.85
+2.26 (2.27%)
Jun 24, 2026, 11:31 AM EDT - Market open
2.27% (1D)
| Assets | $163.75M |
| Expense Ratio | 0.94% |
| PE Ratio | 23.19 |
| Shares Out | 1.55M |
| Dividend (ttm) | $1.26 |
| Dividend Yield | 1.25% |
| Ex-Dividend Date | Jun 23, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 27.33% |
| Volume | 33,988 |
| Open | 101.00 |
| Previous Close | 99.59 |
| Day's Range | 100.91 - 104.50 |
| 52-Week Low | 66.00 |
| 52-Week High | 123.80 |
| Beta | 1.71 |
| Holdings | 70 |
| Inception Date | Jun 15, 2011 |
About CURE
Fund Home PageThe Direxion Daily Healthcare Bull 3X ETF (CURE) is an exchange-traded fund that is based on the S&P Health Care Select Sector index. The fund provides 3x levered exposure to a market cap weighted sub-index of the S&P 500 that tracks the performance of US listed health care companies. CURE was launched on Jun 15, 2011 and is issued by Direxion.
Asset Class Equity
Category Trading--Leveraged Equity
Region North America
Stock Exchange NYSEARCA
Ticker Symbol CURE
ETF Provider Direxion
Index Tracked S&P Health Care Select Sector
Top 10 Holdings
67.20% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 12.23% |
| Dreyfus Govt Cash Man Ins | n/a | 10.52% |
| Goldman Sachs Fin Gov 465 Institut | n/a | 8.94% |
| Goldman Finl Sq Trsry Inst 506 | n/a | 8.32% |
| Johnson & Johnson | JNJ | 7.73% |
| AbbVie Inc. | ABBV | 5.38% |
| UnitedHealth Group Incorporated | UNH | 5.10% |
| Merck & Co., Inc. | MRK | 3.97% |
| Amgen Inc. | AMGN | 2.55% |
| Thermo Fisher Scientific Inc. | TMO | 2.45% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 23, 2026 | $0.3746 | Jun 30, 2026 |
| Mar 24, 2026 | $0.28317 | Mar 31, 2026 |
| Dec 23, 2025 | $0.29121 | Dec 31, 2025 |
| Sep 23, 2025 | $0.31013 | Sep 30, 2025 |
| Jun 24, 2025 | $0.30549 | Jul 1, 2025 |
| Mar 25, 2025 | $0.34549 | Apr 1, 2025 |
Performance
CURE had a total return of 37.53% in the past year, including dividends. Since the fund's inception, the average annual return has been 23.10%.
News
Biocure Technology Inc. enters into exclusive Letter Agreement to acquire Glorious Success Limited in Reverse Takeover Transaction
VANCOUVER, British Columbia - TheNewswire - June 22 , 2026 -- Biocure Technology Inc. (“CURE” or the “Company”) (CSE: CURE) announces that it has entered into a binding letter agreement dated June 22...
1 day ago - TheNewswire